Details of the Drug

General Information of Drug (ID: DMTL94F)

Drug Name

Maraviroc

Synonyms

376348-65-1; Selzentry; Celsentri; UK-427857; UK-427,857; UK 427857; UNII-MD6P741W8A; MD6P741W8A; CHEMBL256907; MVC; CHEMBL1201187; CHEBI:63608; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[321]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; Maraviroc [USAN]; Celsentri (TN); Celsentri(TM); PRO 140 & Maraviroc; Selzentry (TN); Selzentry(TM); UK-427,857 maraviroc (MVC); Exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; [3H]maraviroc

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Approved	[1], [2], [3]
Chronic obstructive pulmonary disease	CA22	Phase 3	[1], [3]

Therapeutic Class

Anti-HIV Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 2

Molecular Weight (mw)

513.7

Topological Polar Surface Area (xlogp)

5.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: The bioavailability of drug is 23% [5]
Clearance: The drug present in the plasma can be removed from the body at the rate of 9.4 mL/min/kg [6]
Elimination: 8% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 14 - 18 hours [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 33.373 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.25% [6]
Vd: The volume of distribution (Vd) of drug is 194 L [8]

Chemical Identifiers

Formula: C29H41F2N5O
IUPAC Name: 4,4-difluoro-N-[(1S)-3-[(1S,5R)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
Canonical SMILES: CC1=NN=C(N1C2C[C@H]3CC[C@@H](C2)N3CC[C@@H](C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C
InChI: InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25?,26-/m0/s1
InChIKey: GSNHKUDZZFZSJB-HLMSNRGBSA-N

Cross-matching ID

PubChem CID: 3002977
ChEBI ID: CHEBI:63608
CAS Number: 376348-65-1
DrugBank ID: DB04835
TTD ID: D0NR6S
VARIDT ID: DR00730
ACDINA ID: D00384

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-C chemokine receptor type 5 (CCR5)	TT2CEJG	CCR5_HUMAN	Antagonist	[9], [10], [11]
CCR5 messenger RNA (CCR5 mRNA)	TTJIH8Q	CCR5_HUMAN	Antagonist	[12]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification

12 Disease of the respiratory system

Disease Class

ICD-11: CA23 Asthma

The Studied Tissue

Lung tissue

The Studied Disease

Chronic obstructive pulmonary disease [ICD-11:CA23]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
C-C chemokine receptor type 5 (CCR5)	DTT	CCR5	5.10E-01	0.03	0.05
C-C chemokine receptor type 5 (CCR5)	DTT	CCR5	5.43E-01	1.04E-02	0.02
P-glycoprotein 1 (ABCB1)	DTP	P-GP	1.24E-01	-4.12E-01	-4.68E-01
P-glycoprotein 1 (ABCB1)	DTP	P-GP	3.00E-02	-1.09E-02	-7.37E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Maraviroc

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Maraviroc caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[33]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Maraviroc caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[33]
-----------

Coadministration of a Drug Treating the Disease Different from Maraviroc (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sarecycline	DMLZNIQ	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by Sarecycline .	Acne vulgaris [ED80]	[34]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Maraviroc caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[33]
Midostaurin	DMI6E0R	Moderate	Decreased metabolism of Maraviroc caused by Midostaurin mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[34]
Arn-509	DMT81LZ	Major	Increased metabolism of Maraviroc caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[34]
Gilteritinib	DMWQ4MZ	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[34]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Maraviroc caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[34]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Maraviroc and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[35]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Maraviroc caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[34]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[36]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Maraviroc and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[37]
HKI-272	DM6QOVN	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by HKI-272.	Breast cancer [2C60-2C6Y]	[34]
Tucatinib	DMBESUA	Major	Decreased metabolism of Maraviroc caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[34]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Maraviroc caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[34]
Alpelisib	DMEXMYK	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by Alpelisib.	Breast cancer [2C60-2C6Y]	[34]
PF-04449913	DMSB068	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[34]
Ulipristal	DMBNI20	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by Ulipristal.	Contraceptive management [QA21]	[34]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Maraviroc caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[34]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Maraviroc caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[34]
MK-8228	DMOB58Q	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by MK-8228.	Cytomegaloviral disease [1D82]	[34]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Maraviroc caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Maraviroc caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Maraviroc and Cannabidiol.	Epileptic encephalopathy [8A62]	[38]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Maraviroc caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[33]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Maraviroc caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[34]
Telaprevir	DMMRV29	Major	Decreased metabolism of Maraviroc caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[34]
Daclatasvir	DMSFK9V	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by Daclatasvir.	Hepatitis virus infection [1E50-1E51]	[34]
GS-5885	DMSL3DX	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by GS-5885.	Hepatitis virus infection [1E50-1E51]	[34]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Maraviroc and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[39]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Maraviroc and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[40]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Maraviroc and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[41]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Maraviroc and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[42]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[34]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Maraviroc caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[34]
Suvorexant	DM0E6S3	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by Suvorexant.	Insomnia [7A00-7A0Z]	[34]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Maraviroc caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[34]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Maraviroc caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[43]
Ceritinib	DMB920Z	Major	Decreased metabolism of Maraviroc caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[34]
PF-06463922	DMKM7EW	Moderate	Accelerated clearance of Maraviroc due to the transporter induction by PF-06463922.	Lung cancer [2C25]	[33]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Maraviroc caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[34]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Maraviroc caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[34]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Maraviroc and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[44]
Idelalisib	DM602WT	Major	Decreased metabolism of Maraviroc caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[34]
Ibrutinib	DMHZCPO	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by Ibrutinib.	Mature B-cell lymphoma [2A85]	[38]
Ponatinib	DMYGJQO	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by Ponatinib.	Mature B-cell lymphoma [2A85]	[34]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Maraviroc caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[33]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[45]
Flibanserin	DM70DTN	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by Flibanserin.	Mood disorder [6A60-6E23]	[34]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Maraviroc and Ozanimod.	Multiple sclerosis [8A40]	[46]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Maraviroc caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[34]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Maraviroc caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[34]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[47]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Maraviroc caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[34]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Maraviroc and Safinamide.	Parkinsonism [8A00]	[46]
Istradefylline	DM20VSK	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by Istradefylline.	Parkinsonism [8A00]	[34]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Maraviroc caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[48]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Maraviroc caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[49]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Maraviroc caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[34]
Enzalutamide	DMGL19D	Major	Increased metabolism of Maraviroc caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[34]
Voxelotor	DMCS6M5	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by Voxelotor.	Sickle-cell disorder [3A51]	[34]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Maraviroc caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[38]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Maraviroc caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[34]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Maraviroc and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[38]
Armodafinil	DMGB035	Moderate	Increased metabolism of Maraviroc caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[33]
LEE011	DMMX75K	Moderate	Decreased metabolism of Maraviroc caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[34]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Maraviroc caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[50]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Maraviroc caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[34]
Cabozantinib	DMIYDT4	Moderate	Decreased clearance of Maraviroc due to the transporter inhibition by Cabozantinib.	Thyroid cancer [2D10]	[34]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Maraviroc caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[33]
-----------


⏷ Show the Full List of 68 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 2	E00446	2723854	Colorant
Calcium hydrogenphosphate	E00294	24441	Diluent
Magnesium stearate	E00208	11177	lubricant
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Maraviroc 150 mg tablet	150 mg	Oral Tablet	Oral
Maraviroc 25 mg tablet	25 mg	Oral Tablet	Oral
Maraviroc 300 mg tablet	300 mg	Oral Tablet	Oral
Maraviroc 75 mg tablet	75 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 806).
2	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
3	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
4	BDDCS applied to over 900 drugs
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
9	Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists. Antiviral Res. 2009 Jul;83(1):86-9.
10	Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell. 1999 Mar 5;96(5):667-76.
11	Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry. 1996 Mar 19;35(11):3362-7.
12	Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol. 2005 Dec 19;71(1-2):163-72.
13	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
14	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
15	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
16	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
17	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
18	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
19	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
20	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
21	HIV entry: new insights and implications for patient management. Curr Opin Infect Dis. 2009 Feb;22(1):35-42.
22	Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication. J Pharmacol Exp Ther. 2011 Jun;337(3):655-62.
23	Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int Immunopharmacol. 2007 Dec 5;7(12):1528-34.
24	The return of PRO 140, a CCR5-directed mAb. Curr Opin HIV AIDS. 2018 Jul;13(4):346-353.
25	The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. J Antimicrob Chemother. 2015 Mar;70(3):750-6.
26	A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
27	Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV. N Engl J Med. 2014 March 6; 370(10): 901-910.
28	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798). J Med Chem. 2011 Jan 13;54(1):67-77.
29	Tapping into combination pills for HIV. Nat Rev Drug Discov. 2009 Jun;8(6):439-40.
30	Progress on RNAi-based molecular medicines. Int J Nanomedicine. 2012; 7: 3971-3980.
31	Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005 Dec;49(12):4911-9.
32	A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 1997 Sep 12;277(5332):1656-9.
33	Cerner Multum, Inc. "Australian Product Information.".
34	Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
35	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
36	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
37	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
38	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
39	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
40	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
41	Canadian Pharmacists Association.
42	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
43	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
44	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
45	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
46	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
47	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
48	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
49	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
50	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.